# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Joseph Catanzaro maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Overweight and maintains $12...
HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profil...
HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the pri...
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimat...
Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price tar...